Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the ...
The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.
Analysts expect the New York-based company to report quarterly earnings at 46 cents per share, up from 10 cents per share in ...
In other words, I view the insider buy as a vote of confidence in PFE for 2025. As a key holding for my income portfolio, a steady business trend tends to lead to a stable stock price, which is ...
However, Pfizer's revenue guidance for 2025 doesn't look particularly exciting. The company expects its top line to come in ...
Pfizer posted Q4 revenue of $17.76 billion, up 22% YoY, with strong sales from Paxlovid, Vyndaqel, and Eliquis. The company reaffirmed its 2025 revenue outlook.
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Rezolute (RZLT – Research Report) and Pfizer (PFE – Research ...
22hon MSN
We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback